MT-601

· Marker Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MT-601, covering 2024-08-12 to 2025-08-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma [Phase 1]